PointState Capital’s Biogen BIIB Stock Holding History

PointState Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,000	Closed	-$5.04M	–	77
2021 Q4	$5.04M	Sell	21,000 -44,500	-68%	-$11.4M	0.08%	88
2021 Q3	$18.5M	Buy	65,500 +24,900	+61%	+$8.16M	0.31%	60
2021 Q2	$14.1M	Sell	40,600 -6,800	-14%	-$2.06M	0.24%	68
2021 Q1	$13.3M	Buy	47,400 +38,900	+458%	+$10.5M	0.26%	70
2020 Q4	$2.08M	Buy	+8,500	New	+$2.19M	0.04%	111
2020 Q3	–	Sell	-56,995	Closed	-$15.2M	–	107
2020 Q2	$15.2M	Buy	+56,995	New	+$17.1M	0.46%	43
2020 Q1	–	Sell	-98,887	Closed	-$29.3M	–	71
2019 Q4	$29.3M	Buy	+98,887	New	+$27.4M	0.53%	44
2019 Q2	–	Sell	-4,500	Closed	-$1.06M	–	113
2019 Q1	$1.06M	Buy	+4,500	New	+$1.42M	0.02%	113
2018 Q3	–	Sell	-86,900	Closed	-$25.2M	–	144
2018 Q2	$25.2M	Sell	86,900 -60,405	-41%	-$17M	0.29%	67
2018 Q1	$40.3M	Sell	147,305 -620,912	-81%	-$193M	0.44%	62
2017 Q4	$245M	Buy	768,217 +493,787	+180%	+$158M	2.38%	11
2017 Q3	$85.9M	Buy	274,430 +118,500	+76%	+$35.1M	0.73%	36
2017 Q2	$42.3M	Sell	155,930 -177,570	-53%	-$47M	0.46%	52
2017 Q1	$91.2M	Buy	+333,500	New	+$94.3M	0.95%	31
2016 Q4	–	Sell	-210,000	Closed	-$65.7M	–	123
2016 Q3	$65.7M	Buy	+210,000	New	+$62.2M	0.68%	38
2015 Q3	–	Sell	-139,200	Closed	-$56.2M	–	96
2015 Q2	$56.2M	Sell	139,200 -318,800	-70%	-$128M	0.66%	38
2015 Q1	$193M	Buy	458,000 +333,000	+266%	+$131M	2.62%	9
2014 Q4	$42.4M	Buy	+125,000	New	+$40.4M	0.72%	42

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

PointState Capital's BIIB Position: Q1 2022 in Review

PointState Capital sold out of Biogen (BIIB) in Q1 2022, closing a stake of 21,000 shares — an estimated $5.04M sold.

PointState Capital first reported a position in BIIB in Q4 2014 and held it in 18 quarters. The position peaked at $245M in Q4 2017. 951 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

PointState Capital reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 21,000 Biogen shares in Q1 2022, an estimated $5.04M.
PointState Capital first reported a position in Biogen in Q4 2014 and held it in 18 quarters.
PointState Capital's Biogen position peaked at $245M in Q4 2017.
951 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.